Skip to main content

Anti-Rheumatic Rx

RT @EBRheum: NEW ANCA Associated Vasculitis Guidelines - discussed at #ACR19 1. Rituxan > cytoxan2. Reduced steroid regimen!3. Rec agai…

Mike Putman EBRheum

6 months 2 weeks ago

NEW ANCA Associated Vasculitis Guidelines - discussed at #ACR19 1. Rituxan > cytoxan 2. Reduced steroid regimen! 3. Rec against PLEX 4. Rec FOR scheduled RTX over ANCA+B cell guided 5. MTX for limited dx Well done everyone - very reasonable and evidence based! @RheumNow https://t.co/oX6qEJDQON

RT @drdavidliew: @cappelliMD @Richter_MD @LCalabreseDO @CCalabreseDO @lexmeara @UmaThanaMD Nice work @Richter_MD - such an important phenom…

David Liew drdavidliew

6 months 3 weeks ago
@cappelliMD @Richter_MD @LCalabreseDO @CCalabreseDO @lexmeara @UmaThanaMD Nice work @Richter_MD - such an important phenomenon. It’s always something nice to tell my melanoma irAE patients: your arthritis might be nasty, but at least there’s a substantive upside! #ACR19 ABST2137 @RheumNow (sorry to miss you in person!) https://t.co/x1T9n9eekG
RT @hausmannMD: Amazing! Most patients with systemic JIA who receive anakinra as first line monotherapy achieved drug-free remission. Dr Ra…

Jonathan Hausmann MD hausmannMD

6 months 2 weeks ago

Amazing! Most patients with systemic JIA who receive anakinra as first line monotherapy achieved drug-free remission. Dr Ravelli  #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/cWUdUo6dmM

RT @DrPetryna: #ACR19 @rheumnow abs1759 1-y prospective, monocentric, DB, PBO-cont stdy MTX (10mg/wk) vs PBO in erosive hand OA demonstrate…

Olga Petryna DrPetryna

6 months 3 weeks ago

#ACR19 @rheumnow abs1759 1-y prospective, monocentric, DB, PBO-cont stdy MTX (10mg/wk) vs PBO in erosive hand OA demonstrates no improvement in VAS pain score with MTX. at the same time MTX significantly ⬇️progression of joint damage vs PBO & seems to facilitate bone remodeling

SELECT-MONOTHERAPY Trial: Dr. Mike Putman

Dr. Mike Putman discusses his takeaway from the SELECT-MONOTHERAPY trial at the 2019 ACR/ARP annual meeting in Atlanta. 

RT @KDAO2011: #ACR19 @rheumnow Abstr#L09:NORD-STAR trial: DMARD vs biologic 1st line Rx for early RAAll got MTX 25mg/wk x1 month then ran…

k dao KDAO2011

6 months 3 weeks ago

#ACR19 @rheumnow Abstr#L09: NORD-STAR trial: DMARD vs biologic 1st line Rx for early RA All got MTX 25mg/wk x1 month then randomized to pred 20mg/taper to 5mg/d in 9 wks v. SSZ 2g bid v. HCQ 35 mg/wk + joint injx v. CZP v. TCZ v. ABT High remiss in all group (best w/ABT)

A Focus on WOCBA (Women of Childbearing Age)
Maeve Gamble, MD
Many rheumatic diseases affect women of childbearing age. In the age of biologic therapy, women are achieving better disease activity and there are increasing numbers of women with rheumatic diseases…
RT @KDAO2011: #acr19 @rheumnow abstr#0849 #ACRbest French database: Risk for CA in RA with biologics compared to traditional sDMARDS: n=…

k dao KDAO2011

6 months 3 weeks ago

#acr19 @rheumnow abstr#0849 #ACRbest French database: Risk for CA in RA with biologics compared to traditional sDMARDS: n= 83,659 1. No ⬆️ risk solid malig 2. HR lymphoma 1.35. p value not sig 3. NO diff CA b/t biologic monoRx vs comb biologic + DMARD *nonmelanomatous skin CA

RA rheumatoid hands
Tapering of Therapy in RA: Maybe not so Aggressive Next Time
Philip Robinson, MD
This ACR has seen some more great work on tapering of therapy in rheumatoid arthritis. It’s a hot topic and one which I get asked about all the time by my patients. Commonly when I start oral…
×